London · Delayed Price · Currency is GBP · Price in SEK Immunovia AB Statistics
Total Valuation
Immunovia AB has a market cap or net worth of GBP 9.95 million. The enterprise value is 9.44 million.
| Market Cap | 9.95M |
| Enterprise Value | 9.44M |
Important Dates
The next estimated earnings date is Tuesday, February 24, 2026.
| Earnings Date | Feb 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 672.67M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +347.58% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 3.13% |
| Owned by Institutions (%) | 2.34% |
| Float | 651.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 160.33 |
| PB Ratio | -15.26 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.95 |
| EV / Sales | 146.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.63
| Current Ratio | 0.63 |
| Quick Ratio | 0.63 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.46 |
Financial Efficiency
Return on equity (ROE) is -827.51% and return on invested capital (ROIC) is -225.69%.
| Return on Equity (ROE) | -827.51% |
| Return on Assets (ROA) | -116.92% |
| Return on Invested Capital (ROIC) | -225.69% |
| Return on Capital Employed (ROCE) | 1,141.12% |
| Weighted Average Cost of Capital (WACC) | 51.60% |
| Revenue Per Employee | 5,171 |
| Profits Per Employee | -825,802 |
| Employee Count | 12 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -59.10% in the last 52 weeks. The beta is 2.76, so Immunovia AB's price volatility has been higher than the market average.
| Beta (5Y) | 2.76 |
| 52-Week Price Change | -59.10% |
| 50-Day Moving Average | 0.40 |
| 200-Day Moving Average | 4.10 |
| Relative Strength Index (RSI) | 32.81 |
| Average Volume (20 Days) | 64,779 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Immunovia AB had revenue of GBP 62,056 and -9.91 million in losses. Loss per share was -4.08.
| Revenue | 62,056 |
| Gross Profit | 59,213 |
| Operating Income | -7.44M |
| Pretax Income | -9.91M |
| Net Income | -9.91M |
| EBITDA | -7.18M |
| EBIT | -7.44M |
| Loss Per Share | -4.08 |
Balance Sheet
The company has 2.10 million in cash and 1.61 million in debt, with a net cash position of 489,733.
| Cash & Cash Equivalents | 2.10M |
| Total Debt | 1.61M |
| Net Cash | 489,733 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -652,057 |
| Book Value Per Share | -0.00 |
| Working Capital | -1.33M |
Cash Flow
| Operating Cash Flow | -6.86M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 95.42% |
| Operating Margin | -11,990.37% |
| Pretax Margin | -15,968.84% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immunovia AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -347.58% |
| Shareholder Yield | -347.58% |
| Earnings Yield | -99.60% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Immunovia AB has an Altman Z-Score of -54.14 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -54.14 |
| Piotroski F-Score | 2 |